drugset
drugset / Trial / NCT05403281

A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

NCT05403281 ↗

Phase 1 Completed 41 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6012 and each component in healthy adult volunteers.

Timeline

Start
2021-11-05
Primary completion
2021-12-03
Completion
2022-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject DW6012 Unknown — Oral
Subject Dapagliflozin Small molecule — Oral
Subject Sitagliptin Small molecule — Oral

Indications

No indication recorded.